メインコンテンツに移動する
JapaneseホームNewsホーム
Story
13/50

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook  BioMarin Pharmaceutical BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion  The Wall Street Journal BioMarin CEO says $4.8 billion Amicus deal will lead to cost savings and revenue growth  statnews.com BioMarin Soars 20% On A 'Significant' Rare-Disease Buyout  Investor's Business Daily BioMarin is buying Amicus Therapeutics for $4.8 billion  Inquirer.com

Latest News